Literature DB >> 9783687

Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11-13-year-old schoolgirls.

H A Cubie1, M Plumstead, W Zhang, O de Jesus, L A Duncan, M A Stanley.   

Abstract

To allow meaningful approaches to vaccine development, it is important to know the extent of exposure to human papillomavirus (HPV) within the general population, and particularly the age at which the at risk population is infected. The humoral response to human papillomavirus is directed largely to conformationally-dependent epitopes on the whole virion. Virus-like particles (VLPs) of HPV types 1, 2, and 16 were produced using a baculovirus expression system, and were used in the intact state as antigen in an indirect ELISA. Anonymised serum samples from a cohort of Edinburgh schoolgirls were tested for the presence of IgG antibodies directed against the VLPs. The reproducibility of the ELISA was assured by repeated testing of control samples, and by testing all samples in duplicate and, where possible, on several occasions. Of 1,192 tested with the HPV16 VLPs, 90 (7.6%) were classified as clearly positive, and a further 87 (7.3%) were positive but close to the cutoff calculated by comparison with a group of consistently negative sera. Antibodies to HPV2 were detected in 37.5% (407/1,139) and antibodies to HPV 1 in 51.9% (558/1,076) of the schoolgirls. Antibodies to both HPV1 and HPV2 were found frequently, being present in 29.7% (295/ 993) of samples tested; 40 samples had antibodies to all three types. The significance of these results is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783687

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine.

Authors:  Alba E Sanchez; Guillermo Aquino; Pedro Ostoa-Saloma; Juan P Laclette; Leticia Rocha-Zavaleta
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

2.  Review of Gardasil.

Authors:  Diane M Harper; Stephen L Vierthaler; Jennifer A Santee
Journal:  J Vaccines Vaccin       Date:  2010-11-23

Review 3.  [Prophylactic and therapeutic HPV immunization].

Authors:  M Müller; L Gissmann
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

Review 4.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

5.  Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia.

Authors:  Parinda A Mehta; Sharon Sauter; Xue Zhang; Stella M Davies; Suzanne I Wells; Kasiani C Myers; Gitika Panicker; Elizabeth R Unger; Melinda Butsch Kovacic
Journal:  Vaccine       Date:  2017-10-16       Impact factor: 3.641

6.  Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females.

Authors:  Diane M Harper; Stephen L Vierthaler
Journal:  ISRN Obstet Gynecol       Date:  2011-11-02

7.  Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany.

Authors:  Anna Loenenbach; Michael Pawlita; Tim Waterboer; Thomas Harder; Christina Poethko-Müller; Michael Thamm; Raskit Lachmann; Yvonne Deleré; Ole Wichmann; Miriam Wiese-Posselt
Journal:  BMC Infect Dis       Date:  2022-01-10       Impact factor: 3.090

8.  Seroprevalence of 34 human papillomavirus types in the German general population.

Authors:  Kristina M Michael; Tim Waterboer; Peter Sehr; Annette Rother; Ulrich Reidel; Heiner Boeing; Ignacio G Bravo; Jörg Schlehofer; Barbara C Gärtner; Michael Pawlita
Journal:  PLoS Pathog       Date:  2008-06-20       Impact factor: 6.823

9.  T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

Authors:  J C Steele; C H Mann; S Rookes; T Rollason; D Murphy; M G Freeth; P H Gallimore; S Roberts
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.